Recently released federal data shows that in the state of Texas, approximately 10 veterans are taking their lives every week. Various veterans’ organizations and advocates are calling for the state government to find alternative ways, such as psychedelics, to tackle this issue.
In an interview, Navy veteran Marcus Capone revealed that he’d been diagnosed with depression after leaving the military. Capone, who is cofounder of the VETS not-for-profit organization, explained that he turned to psychedelic drugs after current treatments proved to be ineffective. The VETS nonprofit was established to allocate funding for psychedelic therapy and help run as well as support studies on these promising drugs.
Capone stated that the organization had funded more than 500 individuals, many of whom admitted that their experience with psychedelic therapies was life-saving as well as life-changing.
During its last session, legislators in the state of Texas approved a measure that would allow veterans to access alternative therapies.
The Dell Medical School at the University of Texas-Austin, also launched its new Psychedelic Research Therapy Center. The center will commence research on a number of pilot programs that involve mushrooms and veterans. The center’s codirector, Greg Fonzo, stated that one of the programs would examine the use and effectiveness of psilocybin in managing treatment-resistant major depressive disorder. The researchers theorize that this psychedelic may condition the brain of an individual with this mental health indication to become receptive to the treatment process.
Additionally, other universities, including UC Berkley, UC San Francisco and the Johns Hopkins University, are also conducting studies on these substances. For instance, Johns Hopkins released a report earlier this year that demonstrated the effectiveness of psychedelic drugs in the treatment of major depressive disorder.
Research has shown that depression may be associated with suicide. Fonzo explained that the Psychedelic Research Therapy Center was focused on approaching this delicate issue from a place where the risk for individuals involved was minimized.
Researchers hope that studying psychedelics and the effects they induce will help acquire more data on how they work.
The Dell Medical School at the University of Texas-Austin added that it would center its focus on the development and testing of therapies, finding the best ways to prescribe psychedelic drugs and how these drugs psychologically and biologically affect individuals.
The success of the researchers’ studies will be measured by asking patients involved to rate their post-traumatic stress disorder or depression on a scale both before as well as a year after they’ve received psychedelic treatment. Fonzo estimated that these experiments could be conducted in a two-week to three-month period.
Plenty of research is also being undertaken by a number of for-profit entities such as Silo Pharma Inc. (OTCQB: SILO), and there is hope that breakthrough treatments for various neurological conditions may not be far off.
NOTE TO INVESTORS: The latest news and updates relating to Silo Pharma Inc. (OTCQB: SILO) are available in the company’s newsroom at https://ibn.fm/SILO
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 888-902-4192 (U.S. Mobile Phones Only)
For more information please visit https://www.psychedelicnewswire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.psychedelicnewswire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.psychedelicnewswire.com
415.949.5050 Office
Editor@PsychedelicWire.com
PsychedelicNewsWire is part of the InvestorBrandNetwork.
